|Bid||26.99 x 100|
|Ask||27.39 x 100|
|Day's range||27.01 - 27.39|
|52-week range||24.66 - 55.30|
|PE ratio (TTM)||N/A|
|Earnings date||4 May 2017 - 8 May 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||54.17|
Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.
Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.
Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.